Penumbra, Inc. (PEN)

Market Cap	12.54B +27.1%
Revenue (ttm)	1.50B +17.6%
Net Income	160.59M +8.7%
EPS	4.07 +8.8%
Shares Out	39.39M
PE Ratio	78.25
Forward PE	56.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	851,287
Open	321.04
Previous Close	324.04
Day's Range	316.35 - 321.16
52-Week Range	221.26 - 362.41
Beta	0.70
Analysts	Hold
Price Target	362.54 (+13.9%)
Est. Earnings	Nov 9, 2026

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,700
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Analyst Summary

According to 17 analysts, the average rating for PEN stock is "Hold." The 12-month stock price target is $362.54, which is an increase of 13.90% from the latest price.

Price Target

$362.54

(13.90% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 29, 2026

Data Sources Report a data error